Cybin (CYBN) announced unprecedented 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin program in ...

and major depressive disorder (MDD),” said Rob Barrow, Chief Executive Officer of MindMed. “Gregg’s deep expertise in leading the regulatory approvals of transformative psychiatric drugs—demonstrated ...

Cybin (NYSE American: CYBN) (NEO: CYBN) shared promising 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated ps ...

Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...

Shares of Cybin, Inc. ($CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the ...

Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical ...

In September, nine of us gathered in a seminar room in Lattes, in southern France, to begin a two-day first aid training. But the class isn't about performing CPR or treating burns. We're here to ...

TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...

(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe ...

Cybin has reported 71% remission in patients with major depressive disorder (MDD) who received two doses of the psilocin ...

Greenbrook TMS Inc. ("Greenbrook" or the "Company") is pleased to announce that the Company has obtained a final order from the Ontario Superior Court of Justice (Commercial List) approving the ...

A new systematic review from Utrecht University in the Netherlands explores the potential of minor cannabinoids in treating ...